A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings from a phase 2 clinical trial for a new combination therapy for an aggressive, ...

Lilly and Innovent co-developed Tyvyt (sintilimab) in China and launched the drug there together last year as a third-line treatment for Hodgkin's lymphoma. It was the first PD-1 inhibitor to get ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed a phase 3 trial in skin cancer. Novartis had hoped the COMBI-i ...

AKESO (09926.HK) announced the global first-in-class PD-1/VEGF bi-specific antibody ... gene mutations and anaplastic lymphoma kinase (ALK) gene mutations. This indication marks ivonescimab's ...